Meeting
2023 ASCO Annual Meeting
Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.
Authors
Zefei Jiang
Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
Zefei Jiang , Zhigang Yu , Cuizhi Geng , Ying Lin , Zhenzhen Liu , Peifen Fu , Qiang Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
ChiCTR2100041675
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 602)
DOI
10.1200/JCO.2023.41.16_suppl.602
Abstract #
602
Poster Bd #
432
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2012 ASCO Annual Meeting
Pathologic complete response rates observed in women with locally advanced and inflammatory breast cancer receiving neoadjuvant carboplatin and paclitaxel.
First Author: Arvind Manohar Shinde
Poster
2024 ASCO Annual Meeting
Prediction for major pathologic response after neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma by RNA sequencing: A single-arm, phase II trial.
First Author: Wei Guo
Poster
2022 ASCO Annual Meeting
Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
First Author: Laura Spring